- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Michael Morris presents a critical examination of optimal imaging standards for metastatic hormone-sensitive prostate cancer. The presentation explores PSMA imaging's potential while acknowledging its complications such as flare phenomenon and PSMA downregulation. Biographies: Michael Morris, MD, Prostate Cancer Section Head, GU On...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores key questions in metastatic prostate cancer treatment. The panel debates mechanisms behind docetaxel's apparent harm in low-volume metachronous disease while emphasizing patient-centered decision-making, acknowledging that while ADT plus ARPI represents a clear standard of care, other treatment decisions...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Alicia Morgans presents an update on the IRONMAN study, a global real-world data initiative capturing prostate cancer treatment experiences and outcomes. The presentation also discusses the EMPRO substudy, an innovative digital patient monitoring system designed to reduce emergency department visits and improve survival. Biographie...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal examines treatment de-escalation strategies in metastatic hormone-naive prostate cancer. He explores three main approaches: stopping ADT while continuing ARPI, stopping ARPI while maintaining ADT, and revisiting intermittent androgen deprivation therapy, and emphasizes the importance of clinical trials like the P6 p...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Mary-Ellen Taplin discusses the significance of PSA nadir values in metastatic hormone-sensitive prostate cancer treatment, reviewing data from SWOG 9346 and CHAARTED trials that establish PSA nadir as a prognostic indicator while emphasizing that unfavorable PSA decline doesn't necessarily indicate progression. Biographies: Mary-E...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Maria De Santis presents an overview of managing frail patients with metastatic hormone-sensitive prostate cancer. The presentation explores treatment efficacy data and challenges in frail patients, while emphasizing the importance of supportive interventions and individualized treatment approaches. Biographies: Maria De Santis, MD...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Gerhardt Attard discusses the future landscape of prostate cancer treatments and biomarkers, introducing STAMPEDE2's multi-arm trial design. Dr. Attard also addresses key challenges in radiographic progression-free survival measurements, patient selection, and treatment sequencing. Biographies: Gerhardt Attard, MD, PhD, FRCP, John...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Karim Fizazi leads a Q&A session exploring key questions in prostate cancer treatment de-escalation. The panel addresses practical considerations around re-imaging protocols and hormone therapy while highlighting the complexities of designing pragmatic trials that balance patient preferences with clinical outcomes, particularly reg...
|
